Yarrow Bioscience, Inc. (YARW) Financial Statements
Yarrow Bioscience, Inc. (YARW) reported trailing twelve-month revenue of $482000 (up 1.3% year on year) and net income of -$18.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$16.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
YARWYarrow Bioscience, Inc.Follow YARW — free
—
Price chart with a free account
- Market cap
- 51.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.6 | 21.0 | 0.9 | 0.5 | 0.4 | 0.5 | 0.6 | 0.5 | |
| Gross profit | — | 19.6 | -2.4 | — | — | — | — | — | |
| Research & development | 64.5 | 43.5 | 19.5 | 18.4 | 16.3 | 30.9 | 19.2 | — | |
| Operating income | -74.9 | -252.5 | -38.9 | -34.3 | -29.3 | -43.6 | -29.7 | -19.9 | |
| Pre-tax income | -74.0 | -255.8 | -44.7 | -33.9 | -27.9 | -39.8 | -26.7 | -18.9 | |
| Income tax | — | -0.3 | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net income | -74.2 | -255.6 | -73.3 | -23.2 | -28.5 | -39.8 | -26.5 | -18.7 | |
| Diluted EPS ($) | 11.47 | 7.88 | -25.64 | -7.28 | -2.78 | -0.93 | -0.62 | — | |
| Diluted shares (mn) | — | — | 2.9 | 3.2 | 10.3 | 42.6 | 42.8 | — |
USD millions · SEC XBRL
Yarrow Bioscience, Inc. — questions
- What is Yarrow Bioscience, Inc.'s revenue?
- $482000 over the twelve months to 2026-06-30, up 1.3% year on year, from its 10-Q and 10-K filings.
- What is Yarrow Bioscience, Inc.'s net income?
- -$18.7M over the twelve months to 2026-06-30.
- What is Yarrow Bioscience, Inc.'s free cash flow?
- -$16.9M over the twelve months to 2026-06-30.
Every figure on this page comes from Yarrow Bioscience, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.